StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 1.9 %
Shares of NASDAQ:TTNP opened at $4.75 on Wednesday. The company has a 50 day moving average price of $5.70 and a two-hundred day moving average price of $6.15. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- There Are Different Types of Stock To Invest In
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Top Stocks Investing in 5G Technology
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
